• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • Myinsights
  • MYBoard
  • Strategy & Consulting
Select Page
Overview of Key Early-phase CAR T-cell Therapy Studies in Relapsed or Refractory Multiple Myeloma

Overview of Key Early-phase CAR T-cell Therapy Studies in Relapsed or Refractory Multiple Myeloma

by Atif Riaz | Sep 30, 2020 | Featured, Featured News

In this article, we look at some of the early-phase clinical trials, where chimeric antigen receptor (CAR) T-cell therapy has been targeted to the B-cell maturation antigen (BCMA) in patients with relapsed or refractory MM (RRMM). The anti-BCMA CAR T-cell...
What Are Chimeric Antigen Receptor (CAR) T-cells and What is Their Potential Target Site in Multiple Myeloma?

What Are Chimeric Antigen Receptor (CAR) T-cells and What is Their Potential Target Site in Multiple Myeloma?

by Atif Riaz | Sep 21, 2020 | Featured, Featured News

CAR T-cell structure CARs are typically composed of four regions: (1) an extracellular antigen-binding domain; (2) a hinge or spacer peptide; (3) a transmembrane domain that anchors the CAR to the cell membrane; and (4) one or more intracellular signalling domains...

Recent Content

  • NCCN Adds Naxitamab as Category 2A Recommendation for High-Risk Neuroblastoma
  • Providing Care and Listening With Compassion During Cancer
  • Prognostic value and kinetic patterns of measurable residual disease following tandem autologous/allogeneic transplant in newly diagnosed myeloma patients
  • Optimal daratumumab-based regimen for patients with newly diagnosed and previously untreated multiple myeloma: systematic review and component network meta-analysis
  • Tagrisso Therapy Elicits Wave of New Therapeutic Approaches in NSCLC
  • Patient-Centered Management of Dermatologic Toxicities in Oncology: Insights From Cynthia Ryan, PharmD, BCPS
  • Cancer Didn’t Break Me; It Revealed My Strength
  • 2025 Quarter 1 – COA Patient Advocacy Network News Bulletin.
  • EPA Deregulation Means More Air Pollution and More Cancer Deaths
  • FDA Approved NDA for Aficamten to Treat Patients With Obstructive Hypertrophic Cardiomyopathy
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT